reported that patients with diabetes undergoing PCI and in treatment with new OADs (GLP-1 analogs, DPP-4 inhibitors, SGLT2Is) had a reduced incidence of CIN compared to patients with diabetes treated with traditional OADs (metformin, sulfonylureas, thiazolidinediones, insulin). Here, DPP4 is linked to diabetes mellitus.